A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAY x 3702) in ischemic stroke

A. C. Berends, Paul G M Luiten, C. Nyakas

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Repinotan HCl (repinotan, BAY x 3702), a highly selective 5-HT1A receptor agonist with a good record of safety was found to have pronounced neuroprotective effects in experimental models that mimic various aspects of brain injury. Repinotan caused strong, dose-dependent infarct reductions in permanent middle cerebral artery occlusion, transient middle cerebral artery occlusion, and traumatic brain injury paradigms. The specific 5-HT1A receptor antagonist WAY 100635 blocked these effects, indicating that the neuroprotective properties of repinotan are mediated through the 5-HT 1A receptor. The proposed neuroprotective mechanisms of repinotan are thought to be the result of neuronal hyperpolarization via the activation of G protein-coupled inwardly rectifying K+ channels upon binding to both pre- and post-synaptic 5-HT1A receptors. Hyperpolarization results in inhibition of neuron firing and reduction of glutamate release. These mechanisms, leading to protection of neurons against overexcitation, could explain the neuroprotective efficacy of repinotan per se, but not necessarily the efficacy by delayed administration. The therapeutic time window of repinotan appeared to be at least 5 h in in vivo animal models, but may be even longer at higher doses of the drug. Experimental studies indicate that repinotan affects various mechanisms involved in the pathogenesis of brain injury. In addition to the direct effect of repinotan on neuronal hyperpolarization and suppression of glutamate release this compound affects the death-inhibiting protein Bcl-2, serotonergic glial growth factor S-100β and Nerve Growth Factor. It also suppresses the activity of caspase-3 through MAPK and PKCα; this effect may contribute to its neuroprotective efficacy. The dose- and time-dependent neuroprotective efficacy of repinotan indicates that the drug is a promising candidate for prevention of secondary brain damage in brain-injured patients suffering from acute ischemic stroke. Unfortunately, however, the first, randomized, double blind, placebo-controlled clinical trial did not demonstrate the efficacy of repinotan in acute ischemic stroke.

Original languageEnglish
Pages (from-to)379-402
Number of pages24
JournalCNS Drug Reviews
Volume11
Issue number4
Publication statusPublished - Dec 2005

Fingerprint

Serotonin 5-HT1 Receptor Agonists
Receptor, Serotonin, 5-HT1A
Stroke
Middle Cerebral Artery Infarction
Brain Injuries
Glutamic Acid
Serotonin 5-HT1 Receptor Antagonists
Neuregulin-1
Inwardly Rectifying Potassium Channel
Controlled Clinical Trials
Brain
Neuroprotective Agents
Nerve Growth Factor
Secondary Prevention
GTP-Binding Proteins
Caspase 3
Pharmaceutical Preparations
Theoretical Models
Animal Models
Placebos

Keywords

  • Apoptosis
  • BAY x 3702
  • Excitotoxicity
  • Ischemia
  • Neuroprotection
  • Repinotan HCL
  • Stroke

ASJC Scopus subject areas

  • Pharmacology
  • Neuropsychology and Physiological Psychology

Cite this

A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAY x 3702) in ischemic stroke. / Berends, A. C.; Luiten, Paul G M; Nyakas, C.

In: CNS Drug Reviews, Vol. 11, No. 4, 12.2005, p. 379-402.

Research output: Contribution to journalArticle

@article{bd4e60d108ab49d7968983cb39d175a7,
title = "A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAY x 3702) in ischemic stroke",
abstract = "Repinotan HCl (repinotan, BAY x 3702), a highly selective 5-HT1A receptor agonist with a good record of safety was found to have pronounced neuroprotective effects in experimental models that mimic various aspects of brain injury. Repinotan caused strong, dose-dependent infarct reductions in permanent middle cerebral artery occlusion, transient middle cerebral artery occlusion, and traumatic brain injury paradigms. The specific 5-HT1A receptor antagonist WAY 100635 blocked these effects, indicating that the neuroprotective properties of repinotan are mediated through the 5-HT 1A receptor. The proposed neuroprotective mechanisms of repinotan are thought to be the result of neuronal hyperpolarization via the activation of G protein-coupled inwardly rectifying K+ channels upon binding to both pre- and post-synaptic 5-HT1A receptors. Hyperpolarization results in inhibition of neuron firing and reduction of glutamate release. These mechanisms, leading to protection of neurons against overexcitation, could explain the neuroprotective efficacy of repinotan per se, but not necessarily the efficacy by delayed administration. The therapeutic time window of repinotan appeared to be at least 5 h in in vivo animal models, but may be even longer at higher doses of the drug. Experimental studies indicate that repinotan affects various mechanisms involved in the pathogenesis of brain injury. In addition to the direct effect of repinotan on neuronal hyperpolarization and suppression of glutamate release this compound affects the death-inhibiting protein Bcl-2, serotonergic glial growth factor S-100β and Nerve Growth Factor. It also suppresses the activity of caspase-3 through MAPK and PKCα; this effect may contribute to its neuroprotective efficacy. The dose- and time-dependent neuroprotective efficacy of repinotan indicates that the drug is a promising candidate for prevention of secondary brain damage in brain-injured patients suffering from acute ischemic stroke. Unfortunately, however, the first, randomized, double blind, placebo-controlled clinical trial did not demonstrate the efficacy of repinotan in acute ischemic stroke.",
keywords = "Apoptosis, BAY x 3702, Excitotoxicity, Ischemia, Neuroprotection, Repinotan HCL, Stroke",
author = "Berends, {A. C.} and Luiten, {Paul G M} and C. Nyakas",
year = "2005",
month = "12",
language = "English",
volume = "11",
pages = "379--402",
journal = "CNS Drug Reviews",
issn = "1080-563X",
publisher = "Neva Press, Inc.",
number = "4",

}

TY - JOUR

T1 - A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAY x 3702) in ischemic stroke

AU - Berends, A. C.

AU - Luiten, Paul G M

AU - Nyakas, C.

PY - 2005/12

Y1 - 2005/12

N2 - Repinotan HCl (repinotan, BAY x 3702), a highly selective 5-HT1A receptor agonist with a good record of safety was found to have pronounced neuroprotective effects in experimental models that mimic various aspects of brain injury. Repinotan caused strong, dose-dependent infarct reductions in permanent middle cerebral artery occlusion, transient middle cerebral artery occlusion, and traumatic brain injury paradigms. The specific 5-HT1A receptor antagonist WAY 100635 blocked these effects, indicating that the neuroprotective properties of repinotan are mediated through the 5-HT 1A receptor. The proposed neuroprotective mechanisms of repinotan are thought to be the result of neuronal hyperpolarization via the activation of G protein-coupled inwardly rectifying K+ channels upon binding to both pre- and post-synaptic 5-HT1A receptors. Hyperpolarization results in inhibition of neuron firing and reduction of glutamate release. These mechanisms, leading to protection of neurons against overexcitation, could explain the neuroprotective efficacy of repinotan per se, but not necessarily the efficacy by delayed administration. The therapeutic time window of repinotan appeared to be at least 5 h in in vivo animal models, but may be even longer at higher doses of the drug. Experimental studies indicate that repinotan affects various mechanisms involved in the pathogenesis of brain injury. In addition to the direct effect of repinotan on neuronal hyperpolarization and suppression of glutamate release this compound affects the death-inhibiting protein Bcl-2, serotonergic glial growth factor S-100β and Nerve Growth Factor. It also suppresses the activity of caspase-3 through MAPK and PKCα; this effect may contribute to its neuroprotective efficacy. The dose- and time-dependent neuroprotective efficacy of repinotan indicates that the drug is a promising candidate for prevention of secondary brain damage in brain-injured patients suffering from acute ischemic stroke. Unfortunately, however, the first, randomized, double blind, placebo-controlled clinical trial did not demonstrate the efficacy of repinotan in acute ischemic stroke.

AB - Repinotan HCl (repinotan, BAY x 3702), a highly selective 5-HT1A receptor agonist with a good record of safety was found to have pronounced neuroprotective effects in experimental models that mimic various aspects of brain injury. Repinotan caused strong, dose-dependent infarct reductions in permanent middle cerebral artery occlusion, transient middle cerebral artery occlusion, and traumatic brain injury paradigms. The specific 5-HT1A receptor antagonist WAY 100635 blocked these effects, indicating that the neuroprotective properties of repinotan are mediated through the 5-HT 1A receptor. The proposed neuroprotective mechanisms of repinotan are thought to be the result of neuronal hyperpolarization via the activation of G protein-coupled inwardly rectifying K+ channels upon binding to both pre- and post-synaptic 5-HT1A receptors. Hyperpolarization results in inhibition of neuron firing and reduction of glutamate release. These mechanisms, leading to protection of neurons against overexcitation, could explain the neuroprotective efficacy of repinotan per se, but not necessarily the efficacy by delayed administration. The therapeutic time window of repinotan appeared to be at least 5 h in in vivo animal models, but may be even longer at higher doses of the drug. Experimental studies indicate that repinotan affects various mechanisms involved in the pathogenesis of brain injury. In addition to the direct effect of repinotan on neuronal hyperpolarization and suppression of glutamate release this compound affects the death-inhibiting protein Bcl-2, serotonergic glial growth factor S-100β and Nerve Growth Factor. It also suppresses the activity of caspase-3 through MAPK and PKCα; this effect may contribute to its neuroprotective efficacy. The dose- and time-dependent neuroprotective efficacy of repinotan indicates that the drug is a promising candidate for prevention of secondary brain damage in brain-injured patients suffering from acute ischemic stroke. Unfortunately, however, the first, randomized, double blind, placebo-controlled clinical trial did not demonstrate the efficacy of repinotan in acute ischemic stroke.

KW - Apoptosis

KW - BAY x 3702

KW - Excitotoxicity

KW - Ischemia

KW - Neuroprotection

KW - Repinotan HCL

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=33646578468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646578468&partnerID=8YFLogxK

M3 - Article

C2 - 16614737

AN - SCOPUS:33646578468

VL - 11

SP - 379

EP - 402

JO - CNS Drug Reviews

JF - CNS Drug Reviews

SN - 1080-563X

IS - 4

ER -